B
Bull
Bull · 25%IKNA
$1.63
シナリオ価格
$17.160
+0.752 (+4.38%)終値時点
Loading chart…
- High
- 17.755
- Open
- 16.560
- VWAP
- 17.08
- Vol
- 38.10K
- Mkt Cap
- 84.45M
- Low
- 16.320
- Amount
- 650.77K
- EV/EBITDA, TTM
- 0.70
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
バリュエーション指標
The current forward P/E ratio for ImageneBio Inc (IKNA) is -1.74, compared to its 5-year average forward P/E of -2.78.
Alphio AI Price Scenarios for IKNA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
イベントタイムライン
ニュース
2.007-27TipRanksUpcoming Stock Splits This Week (July 28 to August 1) – Stay Invested
8.507-25NewsfilterInmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
8.507-15NewsfilterIkena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
- 8.507-11NASDAQ.COM
ISS And Glass Lewis Support Ikena's Share Issuance For Proposed Inmagene Merger
5.003-28NewsfilterTraws Pharma Announces Management Updates
IKNA FAQ — answered by Alphio AI
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。